Evaluating the surgical success rate of native tissue vaginal repair with or without autologous blood graft augmentation for pelvic organ prolapse: A randomised controlled trial

FBW Gynaecology Plus0 个研究点目标入组 298 人开始时间: 2023年11月17日最近更新: 2023年11月27日

试验速览

暂无简介。

•Participants will be considered eligible for this study if they:
•1. Are female patients over the age of 18
•2. Have been formally diagnosed with pelvic organ prolapse quantification (POPQ) stage 2 of anterior and or posterior compartment with or without apical prolapse, defined as c -1 (cervix or vaginal cuff 1 cm above hymen) or less.
•3. Understand the conditions of the study fully and are willing to participate for the length of the study in its entirety;
•4. Are capable of giving informed consent to their participation in the study.

•The following patients will be deemed unsuitable for inclusion:
•Patients currently suffering any untreated gynaecological cancers.
•Patients with autoimmune disorders requiring anti-platelet medication (antiplatelet drugs weaken the regenerative capacity of autologous blood products and reduces the quality of the graft)
•Patients who are immunocompromised (e.g. lymphoma, AIDS) or have uncontrolled malignant disease.
•Patients on anti-platelet treatment. Using anticoagulants and NSAIDs is not allowed three weeks before and after surgery due to their interference with the scaffold formation.
•Patients who have a mental disability leading to their inability to consent.
•Patients who are pregnant.
•Patients who are uncooperative, known to miss appointments, are unlikely to follow medical instructions, or unable to attend regular scheduled visits.

发起方

FBW Gynaecology Plus